Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Ramucirumab Makes An Impact In Tough-To-Treat Gastric Cancer, But Will It Be Enough?

Executive Summary

The vascular endothelial growth factor inhibitor demonstrated a 1.4 month improvement in overall survival, giving some investors the jitters but encouraging clinician experts, especially given previous targeted drug trial failures.

You may also be interested in...



Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study

Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.

Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical

The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.

Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study

Lilly’s VEGF2-inhibitor failed to meet its primary endpoint of progression-free survival in a Phase III breast cancer study but met the primary endpoint of improved overall survival in an advanced gastric cancer trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel